Background/Aims Alcohol-associated liver disease (ALD) is a public health concern. ALD patients often have psychiatric comorbidities, but the effects of psychiatric interventions on ALD are not well-established. This study explores the prognostic impact of psychiatric intervention on ALD within UK Biobank cohort.
Methods This population-based study included 2,417 ALD patients from the UK Biobank cohort. Psychiatric intervention was defined by a consultation with psychiatrists during hospitalization or a history of medication related to alcohol use disorder and psychiatric comorbidities. Survival analysis was conducted, incorporating propensity score matching (PSM), to precisely assess the impact of psychiatric intervention.
Result s: Among 2,417 ALD patients, those with F10 (mental disorders due to alcohol) codes had poorer survival outcomes. Psychiatric intervention significantly improved the outcomes of both all-cause and liver-related mortality and reduced the incidence of liver cirrhosis. In subgroup or 2-year landmark analyses, psychiatric intervention consistently showed a survival benefit in ALD patients. In the multivariate analysis, psychiatric intervention was identified as a favorable prognostic factor (hazard ratio, 0.780; P=0.002 after PSM).
Conclusions This study demonstrates the favorable effect of psychiatric intervention in ALD patients with psychiatric comorbidities. These findings emphasize the importance of integrated management for ALD patients to address both their medical and psychiatric aspects. Therefore, we suggest the potential benefits of early psychiatric interventions in improving survival outcomes in ALD.
Citations
Citations to this article as recorded by
Educational video modules for alcohol use disorder: A scalable tool to bridge the treatment gap in hepatology Zi-Xiang Jin, Nian-Zhe Sun World Journal of Hepatology.2026;[Epub] CrossRef
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study” Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2025; 31(1): 316. CrossRef
Trends in Concurrent Psychiatric Comorbidities in Alcohol-Associated Liver Disease: A Nationwide Study from 2015–2023 Shu-Yen Chan, Yee Hui Yeo, Hyunseok Kim, Molly Delk, Natchaya Polpichai, Pojsakorn Danpanichkul, Peng-Sheng Ting Digestive Diseases and Sciences.2025;[Epub] CrossRef
Background/Aims Non-alcoholic fatty liver disease (NAFLD) has become a major concern in Korea since its emergence as a dominant cause of chronic liver disease. However, no study has explored its prevalence in adults under 30 years of age. Therefore, we performed a cross-sectional study to investigate the prevalence of NAFLD in Korean men in their early 20s.
Methods We collected data of 596,359 Korean soldiers who participated in a health examination between January 2015 and July 2021. A total of 571,872 individuals were analyzed after excluding those with missing data and hepatitis B antigen positivity. Hepatic steatosis was determined using the hepatic steatosis index (HSI). Participants with HSI >36 were considered to have NAFLD.
Result s: All participants were men, and the mean age was 20.9±1.3 years. Of the 571,872 participants screened, 77,020 (13.47%) were classified as having NAFLD. The prevalence of NAFLD consistently increased from 2015 to 2021 (10.66% vs. 16.44%, P<0.001). Increases from 2015 to 2021 were also noted in the prevalence of hypercholesterolemia, hyperglycemia, and hypertension (P<0.001 for all). The mean body mass index also increased from 23.3±3.0 kg/m2 to 23.9±3.1 kg/m2 between 2015 and 2021 (P<0.001).
Conclusions The prevalence of NAFLD and of other metabolic dysfunctions in Korean men in their early 20s increased from 2015 to 2021.
Citations
Citations to this article as recorded by
Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song Hepatology International.2025; 19(1): 181. CrossRef
Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang Journal of Physical Activity and Health.2025; 22(3): 323. CrossRef
Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang Gut and Liver.2025; 19(1): 116. CrossRef
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease Michelle Thuy Nguyen, Andrew Lian, Frederick Timothy Guilford, Vishwanath Venketaraman Biomedicines.2025; 13(3): 644. CrossRef
Effect of treadmill walking on cardiometabolic risk factors and liver function markers in older adults with MASLD: a randomized controlled trial Jiyoun Kim, Sungju Lee, Yong-Seok Jee BMC Sports Science, Medicine and Rehabilitation.2025;[Epub] CrossRef
Association Between Nonalcoholic Fatty Liver Disease and Risk of Early-onset Colorectal Cancer Seulji Kim, Jin-Hyung Jung, Kyungdo Han, Seong-Joon Koh, Jong Pil Im, Byeong Gwan Kim, Joo Sung Kim, Hyun Jung Lee Clinical Gastroenterology and Hepatology.2025; 23(13): 2550. CrossRef
Prevalence of Non-alcoholic Fatty Liver Disease in Iran: A Systematic Review and Meta-analysis Seidamir P. Tabaeian, Aziz Rezapour, Samad Azari, Mariano Martini, Maryam Saran, Meysam Behzadifar, Saeed Shahabi, Abdollah Sayyad, Ali Tahernejad, N.L. Bragazzi, S.J. Ehsanzadeh, Masoud Behzadifar Journal of Clinical and Experimental Hepatology.2024; 14(1): 101209. CrossRef
Impact of Overseas Deployment on Fatty Liver and Metabolic Diseases Among Korean Soldiers Chang In Han, Jaejun Lee Military Medicine.2024; 189(7-8): e1621. CrossRef
Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu Gut and Liver.2024; 18(5): 888. CrossRef
Serum uric acid and nonalcoholic fatty liver disease Jia Fan, Dongxu Wang Frontiers in Endocrinology.2024;[Epub] CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
Global incidence and prevalence of nonalcoholic fatty liver disease Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee Biomedicine & Pharmacotherapy.2023; 161: 114445. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis Yi-wen Shi, Jian-Gao Fan Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management Anja Geerts, Sander Lefere Clinical and Molecular Hepatology.2023; 29(Suppl): S276. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017 Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park Diabetes & Metabolism Journal.2023; 47(3): 347. CrossRef
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim Alimentary Pharmacology & Therapeutics.2023; 58(3): 322. CrossRef
Analysis of risk factors related to nonalcoholic fatty liver disease: a retrospective study based on 31,718 adult Chinese individuals Ganggang Wang, Xiaowei Shen, Yicun Wang, Huanhua Lu, Hua He, Xiaoliang Wang Frontiers in Medicine.2023;[Epub] CrossRef
A survey on the awareness, current management, and barriers for non-alcoholic fatty liver disease among the general Korean population Jun-Hyuk Lee, Jang Han Jung, Huiyul Park, Joo Hyun Oh, Sang Bong Ahn, Eileen Laurel Yoon, Dae Won Jun Scientific Reports.2023;[Epub] CrossRef
Muscle Mass Adjusted for Body Weight Is Associated with Significant Liver Fibrosis in Young Adults with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study from a Korean Military Hospital Jaejun Lee, Seongjoo Na, Taeyun Kim, Seong-Woo Lee, Myoung Jung Kim, Chang In Han, Si Hyun Bae Journal of Obesity & Metabolic Syndrome.2023; 32(3): 279. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
Navigating ‘grey areas’ and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT Nicola Polverelli, Juan Carlos Hernández-Boluda, Nico Gagelmann, Carmelo Gurnari, Michele Malagola, Fernando Barroso Duarte, Vaneuza A. M. Funke, Caterina Zerbi, Donal P. McLornan Bone Marrow Transplantation.2025; 60(1): 10. CrossRef
Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases Ji Hoon Kim, Suho Kim, Hee-Chul Nam, Chang Wook Kim, Jae-Sung Yoo, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Ho-Jong Chun, Sung-Eun Lee, Jung-Suk Oh, Pil Soo Sung Cureus.2024;[Epub] CrossRef
The Value of Follow‐Up Liver Stiffness Changes Measured by Virtual Touch Quantification Elastography for Predicting Recurrence of Gastroesophageal Varices after Endoscopic Injection Sclerotherapy on Cirrhotic Patients Yayang Duan, Jinfei Zhang, Min Fan, Derun Kong, Chaoxue Zhang, Jose Celso Ardengh Gastroenterology Research and Practice.2024;[Epub] CrossRef
Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with BCR‐ABL negative myeloproliferative neoplasms Marta Davidson, Florence Wong, Mostafa Atri, Hassan Sibai, Dawn Maze, Verna Cheung, Jeannie Callum, Eshetu G. Atenafu, Vikas Gupta American Journal of Hematology.2023;[Epub] CrossRef
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis Jacinta Perram, David M. Ross, Donal McLornan, Krisstina Gowin, Nicolas Kröger, Vikas Gupta, Clinton Lewis, Nico Gagelmann, Nada Hamad American Journal of Hematology.2022; 97(11): 1464. CrossRef
Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Clin Mol Hepatol 2017;23(2):128-137. Published online May 10, 2017
Background/Aims Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
Methods A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.
Result s: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).
Conclusions MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
Citations
Citations to this article as recorded by
Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis Tengfei Si, Qing Shao, Wayel Jassem, Yun Ma, Nigel Heaton International Journal of Surgery.2025; 111(1): 1203. CrossRef
The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ Yuanhao Peng, Hui Nie, Kuo Kang, Xuanxuan Li, Yongguang Tao, Yangying Zhou Cancer Gene Therapy.2025; 32(1): 136. CrossRef
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis Shun-An Zhou, Qing-Mei Zhou, Lei Wu, Zhi-Hong Chen, Fan Wu, Zhen-Rong Chen, Lian-Qun Xu, Bi-Ling Gan, Hao-Sheng Jin, Ning Shi World Journal of Gastrointestinal Oncology.2024; 16(8): 3672. CrossRef
Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Nandini Gupta, Neelkant Verma, Bhoomika Patel Journal of Gastrointestinal Cancer.2024; 55(4): 1485. CrossRef
Clinical significance of exosomal noncoding RNAs in hepatocellular carcinoma: a narrative review Jae Sung Yoo, Min Kyu Kang Journal of Yeungnam Medical Science.2024; 42: 4. CrossRef
Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che Frontiers in Oncology.2023;[Epub] CrossRef
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao Hepatobiliary & Pancreatic Diseases International.2022; 21(2): 134. CrossRef
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study Juxian Sun, Chang Liu, Jie Shi, Nanya Wang, Dafeng Jiang, Feifei Mao, Jingwen Gu, Liping Zhou, Li Shen, Wan Yee Lau, Shuqun Cheng Chinese Medical Journal.2022; 135(19): 2338. CrossRef
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study Dong Hyun Sinn, Hye Won Lee, Yong-Han Paik, Do Young Kim, Yoon Jun Kim, Kang Mo Kim, Si Hyun Bae, Ji Hoon Kim, Yeon Seok Seo, Jae Young Jang, Byoung Kuk Jang, Hyung Joon Yim, Hyung Joon Kim, Byung Seok Lee, Bo Hyun Kim, In Hee Kim, Eun-Young Cho, Jung Il Digestive Diseases and Sciences.2021; 66(1): 315. CrossRef
Survival in untreated hepatocellular carcinoma: A national cohort study Young Ae Kim, Danbee Kang, Hyeyoung Moon, Donghyun Sinn, Minwoong Kang, Sang Myung Woo, Yoon Jung Chang, Boram Park, Sun-Young Kong, Eliseo Guallar, Soo-Yong Shin, Geunyeon Gwak, Joung Hwan Back, Eun Sook Lee, Juhee Cho, Gianfranco D. Alpini PLOS ONE.2021; 16(2): e0246143. CrossRef
Capecitabine Treatment: A Safe and Effective Therapy in the Field of Oncology Linda Beenet Clinical Colorectal Cancer.2021; 20(3): e194. CrossRef
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments Hiroyuki Suzuki, Hideki Iwamoto, Masahito Nakano, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Dan Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hirohisa Yano, A Translational Oncology.2021; 14(11): 101201. CrossRef
The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shengzhou Li, Jiaxuan Xu, Hongya Zhang, Jiaze Hong, Yuexiu Si, Tong Yang, Yujing He, Derry Minyao Ng, Dingcheng Zheng Chemotherapy.2021; 66(4): 124. CrossRef
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis Miao Liu, Junyi Shi, Tong Mou, Yang Wang, Zhongjun Wu, Ai Shen Journal of Gastroenterology and Hepatology.2020; 35(8): 1277. CrossRef
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy Pil Soo Sung, Moon Hyung Choi, Hyun Yang, Soon Kyu Lee, Ho Jong Chun, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Joon-Il Choi, Young Joon Lee, Si Hyun Bae Frontiers in Oncology.2020;[Epub] CrossRef
ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma Tongwang Yang, Yuxue Gao, Daojie Liu, Yang Wang, Jing Wu, Xiaoni Liu, Ying Shi, Dexi Chen Biochemical and Biophysical Research Communications.2019; 508(3): 769. CrossRef
Selective embolization with magnetized microbeads using magnetic resonance navigation in a controlled‐flow liver model François Michaud, Ning Li, Rosalie Plantefève, Zeynab Nosrati, Charles Tremblay, Katayoun Saatchi, Gerald Moran, Alexandre Bigot, Urs O. Häfeli, Samuel Kadoury, An Tang, Pierre Perreault, Sylvain Martel, Gilles Soulez Medical Physics.2019; 46(2): 789. CrossRef
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience Cem Simsek, Ece Esin, Suayib Yalcin Journal of Oncology.2019; 2019: 1. CrossRef
Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis Bo-wen Zhuang, Wei Li, Xiao-hua Xie, Hang-tong Hu, Ming-de Lu, Xiao-yan Xie Japanese Journal of Clinical Oncology.2019; 49(9): 845. CrossRef
Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment Guofei Li, Limei Zhao Drug Delivery.2019; 26(1): 756. CrossRef
Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani World Journal of Gastroenterology.2019; 25(31): 4360. CrossRef
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma Min Kyu Kang, Jung Gil Park, Heon Ju Lee Medicine.2018; 97(17): e0611. CrossRef
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis Jong Hwan Choi, Woo Jin Chung, Si Hyun Bae, Do Seon Song, Myeong Jun Song, Young Seok Kim, Hyung Joon Yim, Young Kul Jung, Sang Jun Suh, Jun Yong Park, Do Young Kim, Seung Up Kim, Sung Bum Cho Cancer Chemotherapy and Pharmacology.2018; 82(3): 469. CrossRef
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer Roberto Filippi, Pasquale Lombardi, Ilaria Depetris, Elisabetta Fenocchio, Virginia Quarà, Giovanna Chilà, Massimo Aglietta, Francesco Leone Expert Opinion on Pharmacotherapy.2018; 19(13): 1451. CrossRef
Liver‑targeted delivery of liposome‑encapsulated curcumol using galactosylated‑stearate Wen‑Jie Li, You‑Wen Lian, Quan‑Sheng Guan, Ning Li, Wen‑Jun Liang, Wen‑Xin Liu, Yong‑Bin Huang, Yi Cheng, Hui Luo Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? Do Young Kim Clinical and Molecular Hepatology.2017; 23(2): 123. CrossRef
Background/Aims The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice.
Methods Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety.
Result s: This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients.
Conclusions In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
Citations
Citations to this article as recorded by
Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung, Journal of Medical Virology.2019; 91(6): 1104. CrossRef
Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong Journal of Medical Virology.2019; 91(12): 2158. CrossRef
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang Clinical and Molecular Hepatology.2019; 25(4): 400. CrossRef
Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K Journal of Viral Hepatitis.2018; 25(10): 1189. CrossRef
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C Isabella Esposito, Sebastián Marciano, Julieta Trinks Expert Opinion on Drug Metabolism & Toxicology.2018; 14(6): 649. CrossRef
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae Clinical and Molecular Hepatology.2017; 23(1): 51. CrossRef
Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh Hepatitis Monthly.2016;[Epub] CrossRef
First
Prev
